Study of Pembrolizumab (MK-3475) versus Placebo after Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Trial Identifier:	3475-054
Sponsor:	MSD
Collaborator:	European Organisation for Research and Treatment of Cancer
Start Date:	July 2015
Primary Completion Date:	January 2018
Study Completion Date:	November 2026
Condition:	Skin Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Protocol Plain Language Summary - English

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.